Skip to content

Drug Eluting Balloon in BIfUrcations Trial

Drug Eluting Balloon in BIfUrcations Trial - DEBIUT

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON31657
Enrollment
70
Registered
2007-11-13
Start date
2007-12-18
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bifurcations lesion coronary artery sclerosis

Interventions

Comparison of three groups : Group A : normal bare metal stent with normal balloons Group B: normal bare metal stent with paclitaxel balloons Group C: paclitaxel eluting stent with normal balloons

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - stable angina pectoris or unstable angina and documented ischemia or silent ischemia. - the target lesion has a major native coronary artery (>2.5 mm) with a stenosis > 50% (on visual assessment) located at a side branch (>2 mm). - de novo lesion

Exclusion criteria

Exclusion criteria: - in stent restenosis of target lesion - severe calcifications with an undilatable lesion during balloon predilatation (PTRA could be considered) - untreated significant lesion greater than 50% diameter stenosis remaining proximal of distal to the target intervention.

Design outcomes

Primary

MeasureTime frame
Angiographic evaluation of reduction of vessel diameter at 6 months follow-up at the treated segments ( incidence of late Lumen Loss )

Secondary

MeasureTime frame
*Target vessel failure* at 6 months follow up. The incidence of Major Adverse Coronary or Cerebral events ( MACCE ) at 6 month follow up.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)